3rd Circ. Wants Arguments Limited To Market In Doryx Row

By Dani Kass (June 29, 2016, 3:20 PM EDT) -- The Third Circuit on Tuesday told counsel for Mylan Pharmaceuticals Inc., Warner Chilcott PLC and Mayne Pharma Group Ltd. that their oral arguments next month in an antitrust case over the acne medication Doryx should be limited to defining a market and proving or disputing anticompetitive conduct....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!